A real world study analysing efficacy and safety of Blinatumomab in patients with relapsed or refractory B-Cell Precursor Acute Lymphoblastic Leukaemia
Latest Information Update: 07 Jan 2021
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2021 New trial record
- 08 Dec 2020 Interim Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology